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Abstract
Background: The aim of this study was to evaluate the success of selective intraarterial radionuclide therapy (SIRT)
with Yttrium-90 (Y-90) microspheres in liver metastases of different tumors. We also interpreted the contribution of
SIRT to survival times according to responder- non responder and hepatic- extra hepatic disease.
Methods: The clinical and follow-up data of 124 patients who were referred to our department for SIRT between
June 2006 and October 2010 were evaluated retrospectively. SIRT has been applied to 78 patients who were
suitable for treatment. All the patients had primary liver tumor or unresectable liver metastasis of different
malignancies. The treatment was repeated at least one more time in 5 patients to the same or other lobes.
Metabolic treatment response evaluated by fluorine-18 fluorodeoxyglucose (F18-FDG) positron emission
tomography/computed tomography (PET/CT) in the 6
th week after treatment. F18-FDG PET/CT was repeated in per
six weeks periods. The response criterion had been described as at least 20% decrease of SUV value. Also in
patients with neuroendocrine tumor serial Gallium-68 (Ga-68) PET/CT was used for evaluation of response. Patients
were divided into 2 groups according to their treatment response.
Results: 68 patients received treatment for the right lobe, seven patients received treatment for the left lobe and 3
patients for both lobes. The mean treatment dose was estimated at 1.62 GBq. In the evaluation of treatment
response; 43(55%) patients were responder (R) and 35 (45%) patients were non-responder (NR) in the sixth week F18-
FDG PET/CT. Mean pretreatment SUVmax value of R group was 11.6 and NR group was 10.7. While only 11 (31%) out
of 35 NR patients had H disease, 30 (69%) out of 43 R patients had H disease (p < 0.05). The mean overall survival
time of R group was calculated as 25.63 ± 1.52 months and NR group’s 20.45 ± 2.11 (p = 0.04). The mean overall
survival time of H group was computed as 25.66 ± 1.52 months and EH group’s 20.76 ± 1.97 (p = 0.09).
Conclusions: SIRT is a useful treatment method which can contribute to the lengthening of survival times in
patients with primary or metastatic unresectable liver malignancies. Also F18-FDG PET/CT is seen to be a successful
imaging method in evaluating treatment response for predicting survival times in this patient group.
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Background
Primary or metastatic tumors of the liver generally have
poor prognosis and are responsible for the shortening of
overall survival times. Radioembolization with Yttrium-
90 (Y-90) labeled microspheres (SIR spheres) (SIRT) is a
palliative treatment method which could be applied to
patients with unresectable liver tumors [1-3]. SIRT, firstly
had been developed for the use of the treatment of unre-
sectable hepatocellular carcinoma patients. Since then it
has been used for the treatment of liver metastasis of dif-
ferent cancers [4-7]. Radiopharmaceutical includes resin
bases microspheres which are labeled as Y-90. The dia-
meter of spheres is approximately 29-35 μm. Although
the portal venous system supplies the majority of the
blood flow of normal liver tissue, liver metastases obtain
almost all their blood flow by the hepatic artery. This
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spheres which are applied to the hepatic artery cause
micro embolization in the hepatic arterioles. In addition,
Y-90 has beta particles, 64 hours’ half-life and a 2.4 mm
tissue penetration. In this way, in addition to mechanical
obstruction, 30-60 Gray radiation doses are delivered to
tumor tissue associated with applied Y-90 doses [8]. As a
result, the surrounding liver tissue is protected.
The aim of this study was to evaluate the success of
SIRT with Y-90 microspheres in liver metastases of dif-
ferent tumors. We also interpreted the contribution of
SIRT to survival times according to responder- non
responder and hepatic- extra hepatic disease.
Patients and method
Patients
The clinical and follow-up data of 124 patients who were
referred to our department for SIRT between June 2006
and October 2010 were evaluated retrospectively. SIRT
has been applied to 78 patients who were suitable for
treatment. Of the remaining 46 out of 124 patients, the
treatment could not have been performed because of the
main contraindications of SIRT such as bilirubin levels>2
mg/dl or 5 fold elevation of AST and ALT levels or albu-
min levels< 3 mg/dl or bulky tumor>70% of liver tissue.
All the patients had unresectable liver metastasis of differ-
ent malignancies (35/78 colorectal, 25/78 hepatocellular,
7/78 gastric, 4/78 breast, 1/78 malign melanoma, 1/78
pancreas, 1/78 renal cell, 1/78 esophagus and 3/78 neu-
roendocrine tumor patients). All the patients had received
chemotherapy for the treatment of primary tumors.
Furthermore, all of them had taken chemotherapy for liver
metastases and they had been accepted as refractory to
chemotherapy. Partial hepatectomy, chemoembolization
and radiofrequency ablation treatment had been per-
formed in 2, 2 and 6 patients respectively. The treatment
was repeated at least one more time in 5 patients to the
same or other lobes.
All the patients underwent liver function tests and
dynamic liner MRI as well as basal F18-FDG PET/CT
examination before the treatment. The first control F18-
FDG PET/CT scan was undergone by all patients 6
weeks after treatment for the evaluation of treatment
response.
The patients were divided into two groups according
to the disease stage; those with only liver metastases (H)
and those with metastases in other organs (EH).
Selective intraarterial radionuclide therapy (SIRT)
In all patients, widely accepted parameters regarding liver
reserve, bone marrow reserve (granulocytes > 1500/μL,
platelets > 60000/μL), and hepatic vascularity were used
as inclusion and exclusion criteria. Liver reserve was eval-
uated using bilirubin, aspartate transaminase (AST),
alanine transaminase (ALT), and alkaline phosphatase
(ALP) levels in blood. A bilirubin level < 2 mg/dl and
AST/ALT/ALP levels less than 5 times the normal upper
limit were required for radioembolization. 10 patients did
not receive the therapy according to these criteria.
Patients with ascites, portal hypertension, portal venous
thrombosis or an expected survival < 3 months were
excluded as well as the patients with contraindications
for angiography and selective visceral catheterization. To
evaluate vascular tree, a therapy-planning angiogram was
performed. With this angiogram, branches of hepatic
artery to the gastrointestinal tract were coiled to prevent
Y-90 reflux to the stomach, i.e. to gastro-duodenal artery
and right gastric artery. At the end of this planning
angiogram, a 150 MBq dose of
99mTc-labelled macroag-
gregated albumin (MAA) was administered through the
catheter in an attempt to detect arteriovenous shunts
from the hepatic arterial system to the pulmonary system
or gastrointestinal tract. After this procedure, gamma
imaging was obtained and regions of interest were drawn
around the liver and lungs in anterior planar images, and
the pulmonary shunt was calculated using the following
equation: pulmonary shunt fraction = ROI lung counts/
(ROI lung counts +R O Iliver counts. Patients with a pulmon-
ary shunt less than 20% were eligible for therapy.
2 patients were excluded because of the pulmonary shunt
higher than 20%. In 78 patients who were suitable for
therapy, the Y-90 dose was adjusted according to the fol-
lowing body surface area method: activity (GBq) = (BSA -
0.2) + tumor volume/total liver volume. The Y-90 resin
microspheres (Sirtex Medical, Australia) were injected
through the hepatic artery catheter under intermittent
fluoroscopic visualization. Within 1 to 24 hours after
microsphere infusion, Bremsstrahlung images were
obtained to confirm that the Y-90 was deposited only in
the liver. All patients were hospitalized overnight and
medications like analgesics, antiemetic, and H2 antago-
nist were administered, if necessary. All patients were
closely monitored until acute or late toxicities were
resolved.
PET/CT imaging
PET/CT images were acquired with GE Discovery ST
PET/CT scanner. During imaging patients were required
to have at least 6 hours fasting and checked if their blood
glucose levels were under 150 mg/dl. Oral contrast agents
were applied to all patients. Images were obtained while
patients were lying in a supine position from vertex to
proximal femur. Whole body F18-FDG PET/CT imaging
was performed approximately 1 hour after an intravenous
injection of 8-10 mCi FDG. During the waiting period
patients rested in a quiet room without receiving muscle
relaxant. PET images were acquired for 4 minutes per bed
position. Emission PET images were reconstructed with
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patient’s integrated F18-FDG PET/CT with the use of a
standardized protocol involving 140 kV, 70 mA, a tube
rotation time of 0.5 s per rotation, a pitch of 6 and a sec-
tion thickness of 5 mm. Patients were allowed to breathe
normally during procedure. Attenuation-correction was
done by PET/CT fusion images on three planes (trans-
axial, coronal and sagittal) and were reviewed on Xeleris
Workstation (GE Medical System). F18-FDG PET/CT
images were evaluated visually and semi-quantitatively by
two experienced nuclear medicine specialists. The num-
ber, location and SUV values of liver lesions were
recorded.
Evaluation of treatment response
Metabolic treatment response evaluated by PET/CT in the
6
th week after treatment. FDG-PET/CT was repeated in
per six weeks periods. The response criterion had been
described as at least 20% decrease of SUV value. Also in
patients with neuroendocrine tumor serial Ga-68 PET/CT
was used for evaluation of response. Patients were divided
into 2 groups according to their treatment response (R =
responder, NR = non-responder).
Statistical analysis
According to R, NR, H and EH groups, overall survival
analysis was performed using Kaplan-Meier method and
comparison was done using the log rank (Mantel-Cox)
test. SPSS version 15.0 was used for statistical analysis. Sta-
tistical significance was as accepted p < 0.05.
Results
Patients
78 patients (49 M; 29 F; mean age: 62.4 ± 2.3 years)
received intraarterial radionuclide therapy with Y-90 micro-
spheres for liver metastasis or primary HCC between June
2006 and October 2010. Although 25 patients had primary
HCC diagnosis, the remainder had unresectable multiple
liver metastases of different cancers (35 colorectal, 7 gastric,
4 breast, 1 pancreas, 1 renal cell, 1 esophagus cancer, 3
neuroendocrine tumor and 1 malignant melanoma).
Radiation Delivery
68 patients received treatment for the right lobe, seven
patients received treatment for the left lobe and 3
patients for both lobes. The mean treatment dose was
estimated at 1.62 GBq (range: 1-1.8 GBq). In all patients,
the leakage to the lungs was less than 20%. Therefore,
neither reduction in the estimated dose nor discontinua-
tion of the treatment was required.
Toxicity
The technical success of the intraarterial delivery of Y-90
microspheres was 100% and none of the patients experi-
enced complications due to angiographic intervention. All
patients experienced post-radioembolization syndrome
characterized by mild abdominal pain, nausea, and sub-
febrile fever. A combination of a non-opioid analgesic, an
antiemetic and a H2 receptor blocker was given to patients
not tolerating these symptoms. Symptoms decreased in
intensity within one week and completely disappeared
within 15 days. No difference has been found in complica-
tion rates between the two lobes. Bremsstrahlung imaging
done 24 hours after treatment did not show any activity
outside the liver. All patients were hospitalized for one
night as a preventive measure and prolonged hospitaliza-
tion was not required by any of the patients.
Response
In the evaluation of treatment response; 43 (55%) patients
were responder (R) (Figure 1, 2, 3) and 35 (45%) patients
were non-responder (NR) in the sixth week F18-FDG
Figure 1 Cumulative survival curves of the R, NR, H and EH subgroups in the whole patient group. Time: months, R: responder, NR:
nonresponder, H: hepatic, EH: extrahepatic.
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was 11.6 and NR group was 10.7. While only 11 (31%) out
of 35 NR patients had H disease, 30 (69%) out of 43 R
patients had H disease (p < 0.05) (Table 1).
Survival analysis
The mean overall survival time of R group was calcu-
lated as 25.63 ± 1.52 months and NR group’s2 0 . 4 5±
2.11 (p = 0.04) (Table 2, 3). The mean overall survival
time of H group was computed as 25.66 ± 1.52 months
and EH group’s 20.76 ± 1.97 (p = 0.09) (Table 4, 5).
The survival curves of the whole patient group, the col-
orectal group and the HCC group, according to the
treatment response and disease stage were demonstrated
in Figure 4, 5 and 6, respectively.
Discussion
As mainly HCC, colorectal cancer and neuroendocrine
tumors; SIRT has been used for the treatment of liver
metastasis of several tumors and primary hepatocellular
cancer. There have been different results in literature
about the success of SIRT in liver metastasis of different
tumors. It has been reported that the efficiency of SIRT
in liver metastases of colorectal cancer was 90% in first-
line therapy and 80% in second-line therapy [9]. In our
p a t i e n tg r o u p ,w ed e t e c t e dar a t eo fr e s p o n s ea s5 5 % .
This rate might appear low, but from a recent study, we
accepted a different response criterion as a 20% decrease
in SUV levels of liver lesions. Our patient group also
included 78 patients with different malignancies. The
biological behavior of liver metastases of different tumor
might vary. Furthermore all the patients received SIRT
as a salvage therapy. Our response rate might have been
affected for these reasons.
We preferred F18-FDG PET/CT for staging before the
treatment and evaluation of treatment response. There
are many advantages of F18-FDG PET/CT in the early
stage after therapy. Firstly, it is known that F18-FDG
Figure 2 Cumulative survival curves of the R, NR, H and EH subgroups in the colorectal group. Time: months, R: responder, NR:
nonresponder, H: hepatic, EH: extrahepatic.
Figure 3 Cumulative survival curves of the R, NR, H and EH subgroups in the HCC group. Survival: months, R: responder, NR:
nonresponder, H: hepatic, EH: extrahepatic.
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methods in evaluating treatment response at the early
period after SIRT [8,10]. Also Wong et al. have reported
that there is a correlation between liver tumor burden
and the presence of extra-hepatic disease detected by
PET/CT before Y-90 microspheres treatment [11]. So,
F18-FDG PET/CT may provide extra information in
predicting the development of extra-hepatic disease.
In different studies, the survival times after Y-90
microsphere treatment of liver metastases had been
reported between 6.7 and 17.0 months [12-20]. These
periods may change according to the microsphere type
used, previous chemotherapy regimens and patient
groups. For this reason, it would be an optimal
approach to make a comparison with an age, diagnosis,
stage and chemotherapy matched control group. Since
in our study, the treatment was applied as a salvage pro-
tocol to most of the patients, it is very difficult to find a
control group which has patients with same diagnosis
and same stage of disease. For this reason we compared
the survival times of our groups to current literature. It
has been calculated that mean survival times of R and
Table 2 The mean and median survival times of the R and NR groups
Means and Medians for Survival Time
Mean
a Median
95% Confidence Interval 95% Confidence Interval
Response Estimate Std. Error Lower Bound Upper Bound Estimate Std. Error Lower Bound Upper Bound
NR 20,452 2,116 16,305 24,598 18,000 1,495 15,070 20,930
R 25,637 1,523 22,652 28,622 - - - -
Overall 23,654 1,279 21,147 26,161 - - - -
a. Estimation is limited to the largest survival time if it is censored.
Table 1 H and EH disease rates of the R and NR groups
No of patients (%) R NR
H 30(69%) 11(31%)
EH 13(31%) 24(69%)
Table 3 Mantel-cox overall comparison of the R and NR groups
Overall Comparisons
Chi-Square df Sig.
Log Rank (Mantel-Cox) 3,915 1 ,048
Test of equality of survival distributions for the different levels of response.
Table 4 The mean and median survival times of the H and EH groups
Means and Medians for Survival Time
Mean
a Median
95% Confidence Interval 95% Confidence Interval
Disease Estimate Std. Error Lower Bound Upper Bound Estimate Std. Error Lower Bound Upper Bound
H 25,666 1,525 22,678 28,655 - - - -
EH 20,769 1,971 19,906 24,633 22,000 - - -
Overall 23,654 1,279 21,147 26,161 - - - -
a. Estimation is limited to the largest survival time if it is censored.
Table 5 Mantel-cox overall comparison of the H and EH groups
Overall Comparisons
Chi-Square df Sig.
Log Rank (Mantel-Cox) 2,768 1 ,096
Test of equality of survival distributions for the different levels of disease.
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= 0.04) respectively. Because the difference between the
two groups was statistically significant, SIRT is seem to
be beneficial in the treatment of liver tumors. However
this study is a retrospectively designed study which has
small heterogeneous patient number, new prospective
randomized studies are needed to support this result.
Also results of this study support the conclusion which
is that FDG PET/CT is a useful method for evaluating
treatment response in patients who have undergone
SIRT for liver metastasis. In the subgroup analysis;
mean overall survival time of colorectal patients group
was found to be 20.5 months while the R and NR
groups’ were 21.35 and 18.28 months respectively. In
the HCC group; the mean overall survival, R and NR
groups’ survival times were 25.8, 18.24 and 29.5 months
respectively.
The treatment response was also evaluated according
to the disease stage with H and EH groups. The mean
overall survival time of the H group was computed as
25.66 ± 1.52 months and EH group’s2 0 . 7 6±1 . 9 7( p=
0.09). The difference between the two groups was not
statistically significant but it was very close to the limit
of p = 0.05. In the subgroup analysis of colorectal
patients group, the mean survival time of H and EH
groups were 23.12 and 17.08 months respectively. In the
HCC group; the H and EH groups’ survivals were 27.2
and 23.9 months respectively. In the separate evaluation
Figure 4 60 years-old male patient who took 1.2GBq Y-90
microsphere therapy to the right lobe of the liver for HCC. 4A,
4B: axial- fused and PET images of the liver before the treatment.
4C, 4D: axial- fused and PET images of the liver after the treatment.
Figure 5 39 years-old male patient who received 1.6 GBq Y-90
microsphere therapy to the right and left lobe in separate
sessions for primary hemangioendothelioma of the liver. 5A;
coronal CT, 18F-FDG PET, fused and maximum intensity projection
images of the whole body before the treatment. 5B; coronal CT,
18F-FDG PET, fused and maximum intensity projection images of
the whole body after the treatment.
Figure 6 54 years-old male patient who received 1.7 GBq Y-90
microsphere therapy to the right and left lobes in separate
sessions for liver metastases of colorectal cancer. 6A; coronal CT,
18F-FDG PET, fused and maximum intensity projection images of
the whole body before the treatment. 6B; coronal CT, 18F-FDG PET,
fused and maximum intensity projection images of the whole body
after the treatment of the right lobe. 6C; coronal CT, 18F-FDG PET,
fused and maximum intensity projection images of the whole body
after the treatment of the left lobe.
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between the R and NR groups and E and EH groups
was not statistically significant. This result could be
related to the fact that the numbers of each patient
group were small in the separated analysis. For this rea-
son, larger prospective randomized new studies are
needed.
Conclusion
SIRT is a useful treatment method which can contribute
to the lengthening of survival times in patients with pri-
mary or metastatic unresectable liver malignancies. Also
F18-FDG PET/CT is seen to be a successful imaging
method in evaluating treatment response for predicting
survival times in this patient group.
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